B+
Bull case
25%
Probability
Target price
$1.50
Analysis reference price unavailable
Analysis 2026-10-30 · RankAlpha Sentiment Codex
CRDF
Cardiff OncologyCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+1Most likely
B
Base case
45%
Probability
Target price
$0.85
Analysis reference price unavailable
Analysis 2026-10-30 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.45
Analysis reference price unavailable
Analysis 2026-10-30 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-30
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+60.0
Score
AI commentary
The October 29 close of $0.912 was approximately 1.6% above October 28, but without a verified Q3 release it cannot be characterized as a post-earnings reaction (https://www.investing.com/equities/trovagene-inc-historical-data). No credible post-print analyst target or estimate revisions were verified. The scheduled earnings trigger therefore increases monitoring urgency, not confidence in a new operating thesis. Social coverage is unavailable.
RankAlpha Sentiment Codex - 2026-10-30
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-11-30eventConfirm Q3 results and updated cash runwayHigh impact
The October 29 earnings trigger is a scheduled follow-up, not a verified release. Cardiff's latest confirmed earnings exhibit reported $34.5 million in June 30 cash and investments, $24.1 million of first-half operating cash use, and a planned Phase 3 start conditional on additional financing [#SEC-8K-2026-08-11] [#10-Q-2026-08-11] (https://www.sec.gov/Archives/edgar/data/1213037/000119312526344645/crdf-ex99_1.htm). A Q3 release and updated runway remain to be confirmed.
2027-03-31eventSecure financing for planned Phase 3 initiationHigh impact
Cardiff planned to initiate the onvansertib Phase 3 trial in first-quarter 2027, explicitly subject to additional financing [#SEC-8K-2026-08-11] (https://www.sec.gov/Archives/edgar/data/1213037/000119312526344645/crdf-ex99_1.htm). Financing terms and the resulting dilution could dominate the near-term equity outcome; the October filing increased authorized common shares to 300 million [#8-K-2026-10-27] (https://www.sec.gov/Archives/edgar/data/1213037/000149315226048720/form8-k.htm).
2028-12-31catalystValidate onvansertib's Phase 2 signal in a registrational trialHigh impact
The selected 30 mg onvansertib plus FOLFIRI/bevacizumab arm showed a 72.2% confirmed response rate versus 42.1% for the control arm in the company's Phase 2 update, but the reported progression-free-survival confidence interval was wide [#SEC-8K-2026-08-11] (https://www.sec.gov/Archives/edgar/data/1213037/000119312526344645/crdf-ex99_1.htm). Phase 3 execution and eventual confirmatory data—not a dated near-term readout—are the longer-term valuation test.
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-30 • Updated nightlySource: Internal modelMethodology